Cemiplimab injection for early-stage skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of invasive squamous cell carcinoma (a type of skin cancer).
- The cancer is between 0.7 cm and 2 cm (roughly the size of a pea to a small grape) after a biopsy.
- The cancer is on your head, neck, hand, or shin.
- Your doctor plans to remove the cancer with a special surgery that checks all margins (like Mohs surgery).
- You are generally in good health (able to do daily activities) and your organ function is adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called cemiplimab (Libtayo) for kidney transplant recipients who have advanced skin cancer (cutaneous squamous cell carcinoma). The treatment aims to help your immune system fight the cancer while managing your transplant medicines to keep your kidney healthy.
This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests combining a skin cream (imiquimod), a laser treatment, and an immunotherapy drug (cemiplimab) before surgery for high-risk basal cell carcinoma. The goal is to see if this combination shrinks tumors enough to make surgery less disfiguring or damaging to nearby functions.
This study tests different ways of using the drug cemiplimab to treat advanced basal cell skin cancer that cannot be removed with surgery or treated with radiation. It aims to find the most effective approach to shrink or control the cancer.
Hear when a new Cutaneous Squamous Cell Carcinoma (CSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.